Time course and prognostic value of serum GFAP, pNFH, and S100β concentrations in dogs with complete spinal cord injury because of intervertebral disc extrusion.
Animals
Biomarkers
/ blood
Dogs
/ blood
Glial Fibrillary Acidic Protein
/ blood
Intermediate Filaments
/ metabolism
Intervertebral Disc Degeneration
/ veterinary
Intervertebral Disc Displacement
/ veterinary
Paralysis
/ blood
Phosphorylation
Prognosis
Prospective Studies
S100 Calcium Binding Protein beta Subunit
/ blood
Spinal Cord Injuries
/ blood
Time Factors
biomarker
intervertebral disc disease
myelomalacia
prognosis
Journal
Journal of veterinary internal medicine
ISSN: 1939-1676
Titre abrégé: J Vet Intern Med
Pays: United States
ID NLM: 8708660
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
20
06
2018
accepted:
18
01
2019
pubmed:
14
2
2019
medline:
11
5
2019
entrez:
14
2
2019
Statut:
ppublish
Résumé
A noninvasive biomarker is needed to predict recovery from severe spinal cord injury (SCI) because of thoracolumbar intervertebral disc extrusion (TL-IVDE). Proteins released from neural and glial cells can be detected in the blood and show promise as prognostic tools, but their concentration is influenced by time after injury. Serum concentrations of glial fibrillary acidic protein (GFAP), phosphorylated neurofilament heavy chain (pNFH), and S100β will follow different time courses; measurement of combinations of these proteins will predict outcome. Thirty-one dogs with TL-IVDE causing paralysis with no pain perception. Prospective study. Serum samples were taken at presentation and intervals over 56 days and banked at -80°C. Glial fibrillary acidic protein, pNFH, and S100β concentrations were measured using ELISA tests and plotted against time from onset of nonambulatory status. Outcome was established at 6 months. The association between biomarker concentration and outcome was examined using logistic regression, receiver operator characteristics curve analysis, and model development. Thirty-one dogs participated, 3/31 (10%) developed progressive myelomalacia and 19/31 (62%) recovered ambulation. Glial fibrillary acidic protein and S100β concentrations rose for the first 1 to 3 days, and were undetectable by 14 and 28 days, respectively. Phosphorylated neurofilament heavy chain concentrations peaked at 14 days and were detectable at 56 days. Glial fibrillary acidic protein concentrations in the first 72 hours after onset of nonambulatory status predicted recovery with an accuracy of 76.7%-89% depending on sample timing. Serum GFAP concentrations can be used to predict outcome in clinically complete SCI. A rapid inexpensive bedside test is needed.
Sections du résumé
BACKGROUND
BACKGROUND
A noninvasive biomarker is needed to predict recovery from severe spinal cord injury (SCI) because of thoracolumbar intervertebral disc extrusion (TL-IVDE). Proteins released from neural and glial cells can be detected in the blood and show promise as prognostic tools, but their concentration is influenced by time after injury.
HYPOTHESIS/OBJECTIVES
OBJECTIVE
Serum concentrations of glial fibrillary acidic protein (GFAP), phosphorylated neurofilament heavy chain (pNFH), and S100β will follow different time courses; measurement of combinations of these proteins will predict outcome.
ANIMALS
METHODS
Thirty-one dogs with TL-IVDE causing paralysis with no pain perception.
METHODS
METHODS
Prospective study. Serum samples were taken at presentation and intervals over 56 days and banked at -80°C. Glial fibrillary acidic protein, pNFH, and S100β concentrations were measured using ELISA tests and plotted against time from onset of nonambulatory status. Outcome was established at 6 months. The association between biomarker concentration and outcome was examined using logistic regression, receiver operator characteristics curve analysis, and model development.
RESULTS
RESULTS
Thirty-one dogs participated, 3/31 (10%) developed progressive myelomalacia and 19/31 (62%) recovered ambulation. Glial fibrillary acidic protein and S100β concentrations rose for the first 1 to 3 days, and were undetectable by 14 and 28 days, respectively. Phosphorylated neurofilament heavy chain concentrations peaked at 14 days and were detectable at 56 days. Glial fibrillary acidic protein concentrations in the first 72 hours after onset of nonambulatory status predicted recovery with an accuracy of 76.7%-89% depending on sample timing.
CONCLUSIONS AND CLINICAL IMPORTANCE
CONCLUSIONS
Serum GFAP concentrations can be used to predict outcome in clinically complete SCI. A rapid inexpensive bedside test is needed.
Identifiants
pubmed: 30758078
doi: 10.1111/jvim.15439
pmc: PMC6430936
doi:
Substances chimiques
Biomarkers
0
Glial Fibrillary Acidic Protein
0
S100 Calcium Binding Protein beta Subunit
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-734Subventions
Organisme : Assisi Animal Health
Organisme : NCI NIH HHS
ID : P01 CA142538
Pays : United States
Organisme : Congressionally Directed Medical Research Programs
ID : W81XWH-11-1-0772
Informations de copyright
© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Références
Vet J. 2013 Aug;197(2):253-8
pubmed: 23499240
J Neurotrauma. 1999 Dec;16(12):1215-24
pubmed: 10619199
World Neurosurg. 2015 May;83(5):867-78
pubmed: 23524031
J Neurotrauma. 2013 Sep 1;30(17):1490-7
pubmed: 23489259
Spinal Cord. 2014 Jun;52(6):428-33
pubmed: 24710150
J Neurotrauma. 2015 May 15;32(10):661-73
pubmed: 25254425
J Vet Intern Med. 2013 Nov-Dec;27(6):1318-33
pubmed: 24010573
Res Vet Sci. 2015 Jun;100:189-96
pubmed: 25957960
Scand J Plast Reconstr Surg Hand Surg. 2001 Dec;35(4):355-9
pubmed: 11878171
Clin Chem Lab Med. 2011 Mar;49(3):425-33
pubmed: 21175377
BMJ. 2013 Apr 04;346:f1757
pubmed: 23558282
J Neurotrauma. 2017 Jun 15;34(12):2007-2018
pubmed: 28230415
Vet Clin North Am Small Anim Pract. 2014 Nov;44(6):1187-99
pubmed: 25199840
J Vet Med Sci. 2013 Jul 31;75(7):949-53
pubmed: 23470323
J Am Vet Med Assoc. 2008 Jul 1;233(1):129-35
pubmed: 18593322
J Neurotrauma. 2018 Feb 15;35(4):609-622
pubmed: 28969486
Pediatrics. 2018 Jun;141(6):
pubmed: 29716980
Neurology. 2010 Nov 16;75(20):1786-93
pubmed: 21079180
J Vet Intern Med. 2010 Jul-Aug;24(4):890-6
pubmed: 20492479
J Am Vet Med Assoc. 2012 Dec 15;241(12):1617-26
pubmed: 23216037
Stem Cell Rev Rep. 2015 Feb;11(1):180-93
pubmed: 25173879
J Neurotrauma. 2018 Feb 1;35(3):500-507
pubmed: 28974151
J Neurotrauma. 2013 Oct 1;30(19):1620-30
pubmed: 23687938
Spine J. 2014 Dec 1;14(12):2918-22
pubmed: 24780247
Acta Neurochir (Wien). 2017 Feb;159(2):209-225
pubmed: 27957604
J Neurotrauma. 2017 Nov 1;34(21):2994-3002
pubmed: 28462632
J Am Vet Med Assoc. 2005 Nov 1;227(9):1454-60
pubmed: 16279391
J Vet Intern Med. 2019 Mar;33(2):726-734
pubmed: 30758078
J Am Vet Med Assoc. 2003 Mar 15;222(6):762-9
pubmed: 12675299
Vet Surg. 2014 Mar;43(3):301-7
pubmed: 24433331
Biochem Biophys Res Commun. 2005 Nov 4;336(4):1268-77
pubmed: 16176808
Int J Crit Illn Inj Sci. 2017 Oct-Dec;7(4):212-217
pubmed: 29291173
J Small Anim Pract. 2002 Apr;43(4):158-63
pubmed: 11996392
Mol Neurobiol. 2018 Mar;55(3):2174-2184
pubmed: 28290147
J Neurotrauma. 2010 Apr;27(4):669-82
pubmed: 20038240
J Vet Intern Med. 2009 Nov-Dec;23(6):1220-6
pubmed: 19780928
Vet Surg. 2014 Mar;43(3):289-93
pubmed: 24467275
Spinal Cord. 2012 Jul;50(7):493-6
pubmed: 22270191
J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):273-9
pubmed: 24935984
J Neurotrauma. 2003 Sep;20(9):853-8
pubmed: 14577863
J Neurotrauma. 2004 Jan;21(1):49-59
pubmed: 14987465
J Neurotrauma. 2014 Sep 15;31(18):1561-9
pubmed: 24786364
J Am Vet Med Assoc. 2016 Feb 15;248(4):386-94
pubmed: 26829270